On September 28, 2025 Santo Therapeutics reported the company successfully completed a tens of millions of RMB angel+ round of financing. This round of financing was exclusively invested by Fir Creek Capital, and the funds raised will be focused on advancing the company’s globally leading lentiviral gene therapy pipeline.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Syntop Biotech stated: "The Fir Creek team’s expertise and long-term commitment to the biotechnology field give us great confidence in our collaboration. This investment not only highly recognizes Syntop Biotech’s leading advantages in the lentiviral vector field, but also reflects the deep synergy between the two companies in the gene therapy industry. We are also very grateful to our existing shareholders for their long-term support, and to our medical partners and patients for their continued support. This financing will help Syntop achieve key milestones and accelerate our dual US and Chinese drug registrations and further research on innovative projects."
Fir Creek Capital stated: "We have always been committed to investing in innovative biotechnologies and therapies such as cell and gene therapy. We are excited about Syntop Biotech’s technological accumulation and breakthroughs in the field of lentiviral vector design. We hope to work with the company to usher in a new era of gene therapy."
(Press release, Santo Therapeutics, SEP 28, 2025, View Source;scene=1&srcid=0225XxejoQWkgy8ZZdODAgrJ&sharer_shareinfo=8d75cf4435709cdf87dcc4e9179111ea&sharer_shareinfo_first=8d75cf4435709cdf87dcc4e9179111ea&from=industrynews&color_scheme=light#rd [SID1234663849])